Promomed will launch production of specialised small‑batch drugs with an investment of 1.4 billion roubles, the company’s press service told GxP News. The relevant agreement was signed at the St Petersburg International Economic Forum by Promomed CEO Alexander Yefremov and Roman Petrutsa, director of the Industrial Development Fund.
With subsidized financing from the Industrial Development Fund totalling 940 million roubles, Promomed will invest in the project to produce small‑batch high‑tech drugs and active pharmaceutical ingredients. This includes, for example, medicines for Duchenne muscular dystrophy or short bowel syndrome.
Production capacity is expected to reach 47,000 packs per year by 2031.
“The needs of patients with rare (orphan) diseases in Russia remain unmet. At the same time, modern medicine is increasingly moving towards personalised therapy, which has proven effective in treating a wide range of conditions. Both directions share a common technological need for small‑batch drug production,” said Pyotr Bely, founder and chairman of the board of directors of Promomed.
However, such industrial capacity is virtually non‑existent in Russia, Bely said.
“As a result, patients depend on foreign manufacturers that have set up niche production. In the current geopolitical situation, such dependence cannot always guarantee supply stability. Moreover, foreign drugs are extremely expensive,” he stressed.
Therefore, the company’s task is to ensure treatment accessibility in the broadest sense, he said.